Aram Bidikian

Clinical outcomes associated with <i>NPM1</i> mutations in patients with relapsed or refractory AML

Ghayas C. Issa, Aram Bidikian, Sangeetha Venugopal et al. · Blood Advances · 2022 · 50 citations · Full text

Mixed-phenotype Acute Leukemia, Pathology, Favorable Prognosis +17

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia

Aram Bidikian, Hagop M. Kantarjian, Elias Jabbour et al. · Blood Cancer Journal · 2022 · 47 citations · Full text

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Ghayas C. Issa, Branko Cuglievan, Courtney D. DiNardo et al. · Blood · 2023 · 44 citations

Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor

Aram Bidikian, Elias Jabbour, Ghayas C. Issa et al. · American Journal of Hematology · 2023 · 31 citations · Full text

Hematological Malignancy, Chronic Myeloid Leukemia, Medicine +13

Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience

Adriana Trabal, Amber Gibson, Jiasen He et al. · Cancers · 2023 · 31 citations · Full text